Migracap Lite Tablet SR is a sustained-release formulation combining the salts propranolol (40mg) and flunarizine (5mg), indicated for the prophylaxis of migraine and cluster headache. Propranolol, a beta-blocker, exhibits its therapeutic effects by reducing the frequency and severity of migraine attacks, while flunarizine, a calcium channel blocker, demonstrates efficacy in preventing migraine and cluster headache recurrences. The sustained-release technology enables a gradual release of the active ingredients over a prolonged period, providing a consistent therapeutic effect. Migracap Lite Tablet SR is suitable for patients who require prolonged prophylactic therapy. The recommended dose is one tablet twice daily, taken with or without food. Patients with a history of angina pectoris, asthma, or chronic obstructive pulmonary disease, and those with a recent myocardial infarction or cardiac failure should be closely monitored. The product may cause dizziness, lightheadedness, or headaches, particularly during the initial phase of treatment. Regular monitoring of blood pressure and electrolyte levels is essential.